Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib For First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)

NCT04950400 is registered in ClinicalTrials.gov with Beijing Chest Hospital as lead sponsor.

NCT NCT04950400
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04950400 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of Camrelizumab Combined With Chemotherapy Sequential Camrelizumab Combined With Apatinib For First-line Treatment of Advanced Non-small Cell Lung Cancer (NSCLC)
Lead sponsor
Beijing Chest Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
July 7, 2021
Completion date
April 4, 2024
Enrollment
60 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

non-small cell lung cancer